A detailed history of Isthmus Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Isthmus Partners, LLC holds 1,725 shares of ABBV stock, worth $288,506. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,725
Previous 2,160 20.14%
Holding current value
$288,506
Previous $334,000 5.99%
% of portfolio
0.04%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$159.82 - $182.1 $69,521 - $79,213
-435 Reduced 20.14%
1,725 $314,000
Q4 2023

Feb 12, 2024

BUY
$137.6 - $154.97 $13,760 - $15,497
100 Added 4.85%
2,160 $334,000
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $16,698 - $19,331
125 Added 6.46%
2,060 $307,000
Q2 2023

Aug 03, 2023

BUY
$132.51 - $164.9 $1,325 - $1,649
10 Added 0.52%
1,935 $260,000
Q3 2021

Nov 10, 2021

BUY
$106.4 - $120.78 $31,920 - $36,234
300 Added 18.46%
1,925 $208,000
Q2 2021

Aug 10, 2021

BUY
$105.21 - $117.21 $170,966 - $190,466
1,625 New
1,625 $183,000
Q3 2020

Nov 04, 2020

SELL
$85.91 - $100.83 $188,658 - $221,422
-2,196 Closed
0 $0
Q2 2020

Aug 10, 2020

SELL
$73.37 - $98.18 $39,839 - $53,311
-543 Reduced 19.82%
2,196 $216,000
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $176,665 - $267,846
2,739 New
2,739 $209,000
Q4 2018

Feb 04, 2019

SELL
$77.85 - $96.01 $125,572 - $154,864
-1,613 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$88.91 - $98.84 $14,314 - $15,913
161 Added 11.09%
1,613 $153,000
Q1 2018

May 11, 2018

SELL
$92.01 - $123.21 $18,402 - $24,642
-200 Reduced 12.11%
1,452 $137,000
Q3 2017

Nov 02, 2017

BUY
$69.85 - $89.22 $115,392 - $147,391
1,652
1,652 $147,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $296B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Isthmus Partners, LLC Portfolio

Follow Isthmus Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Isthmus Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Isthmus Partners, LLC with notifications on news.